An open multicentre pilot study examining the safety, efficacy and tolerability of fast titrated (800 mg/day by day 4) quetiapine in the treatment of schizophrenia/schizoaffective disorder

References

• Buchanan RW, Carpenter WT. Schizophrenia: introduction and overview. Kaplan & Sadock's Comprehensive Textbook of Psychiatry7th ed, BJ Sadock, VA Sadock. Lippincott Williams & Wilkins, Philadelphia, PA 2000; 1096–110
   Google Scholar
• Suppina AL, Patten SB. Self-reported diagnosis of schizophrenia and psychotic disorders may be valuable for monitoring and surveillance. Can J Psychiatry 2006; 51(4)256–9
   Google Scholar
• DeQuardo JR. Pharmacologic treatment of first-episode schizophrenia: early intervention is key to outcome. J Clin Psychiatry 1998; 59(Suppl 19)9–17
   Google Scholar
• DeQuardo JR, Tandon R. Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia?. J Psychiatr Res 1998; 32: 229–42
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Tandon R. Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia. J Clin Psychiatry 2002; 63(Suppl 13)12–20
   Google Scholar
• Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997; 23: 637–51
   PubMed Web of Science ®Google Scholar
• Kampman O, Lehtinen K. Compliance in psychoses. Acta Psychiatr Scand 1999; 100: 167–75
   Web of Science ®Google Scholar
• Oehl M, Hummer M, Fleischhacker WW. Compliance with antipsychotic treatment. Acta Psychiatr Scand Suppl 2000; 102: 83–6
   Google Scholar
• Goldstein JM. The new generation of antipsychotic drugs: how atypical are they?. Int J Neuropsychopharmacol 2000; 3: 339–49
   PubMed Web of Science ®Google Scholar
• Dunner DL. Safety and tolerability of emerging pharmacological treatments for bipolar disorder. Bipolar Disord 2005; 7: 307–25
   PubMedGoogle Scholar
• American Diabetes Association, American PsychiatricAssociation, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity Consensus development conference on the antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596–601.
   Google Scholar
• Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CGG, and the Seroquel Study Group Quetiapine in patients with schizophrenia. Arch Gen Psychiatry 1997;54:549–57.
   PubMed Web of Science ®Google Scholar
• Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 1993; 112: 285–92
   PubMed Web of Science ®Google Scholar
• Kopala LC, Good KP, Milliken H, Buiteman Chr, Woodley H, Rui Q, Whitehorn D, Love L, Balshaw R, Kiss I, Honer WG. Treatment of a first episode of psychotic illness with quetiapine: an analysis of 2 year outcomes. Shizophr Res 2006;81:29–39.
   PubMed Web of Science ®Google Scholar
• Gilbert J, Giner J, Bobes J, Tasalla M, Herranz S, Ovejero C, Rico-Villademoros S. The Seroquel Outcome Study (SOS): efficacy and tolerability of quetiapine in a long-term, naturalistic study of patients with schizophrenia. Int J Psychiatry Clin Pract 2007; 1: 1–11
   Google Scholar
• Pajonk FG. Rapid dose titration of quetiapine for the treatment of acute schizophrenia and acute mania: as case series. J Psychopharmacol 2006; 20: 119–124
   PubMedGoogle Scholar
• Emsley RA, Raniwalla J, Bailey PJ, Jones AM. A comparison of the effects of quetiapine (‘seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol 2000; 15: 121–31
   PubMed Web of Science ®Google Scholar
• Sirota P, Pannet I, Koren A, Tchernichovsky E. Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia. Hum Psychopharmacol Clin Exp 2006; 21: 227–34
   PubMed Web of Science ®Google Scholar
• Mental Health Research Institute and Monash University of Victoria Optimized use of atypical antipsychotics associated with equal efficacy and brief hospital stays in patients with acute psychosis. News Release Tuesday 13 June, 2006.
   Google Scholar
• Smith M, McCoy R, Hamer-Maansson J, Brecher M. Rapid dose escalation with quetiapine, a pilot study. J Clin Psychopharmacol 2005;25(4):331–335.
   Google Scholar
• Arango C, Bobes J. Managing acute exacerbations of schizophrenia: focus on quetiapine. Curr Med Res Opin 2004; 20(5)619–26
   PubMed Web of Science ®Google Scholar
• Kasper S, Müller-Spahn F. Review of quetiapine and its clinical applications in schizophrenia. Expert Opin Pharmacother 2000; 1(4)783–801
   PubMedGoogle Scholar
• Nagy J. Effectiveness of quetiapine up to 1600 mg/day: short-term results with 14-month follow-up. Eur Neuropsychopharmacol 2003; 13(Suppl 4)S340
   Google Scholar
• Bobes J, Garcia-Portilla MP, Saiz PA, Bascaran MT, Bousono M, Arango C. High degree of tolerability for monotherapy with high doses of quetiapine: a case report. J Clin Psychiatry 2002; 63: 1048–9
   PubMed Web of Science ®Google Scholar
• Ganesan S, Levy M, Bilsker D. Effectiveness of quetiapine treatment of aggressive psychosis in the emergency psychiatric setting: a naturalistic pilot study. Poster NR412 presented at the American Psychiatric Association 156th Annual Meeting 2003, San Francisco, , CA, USA, 17–22 May.
   Google Scholar
• Keks N, Tonso M, Tabone K, Thomas R, Tune P, D'Souza R, McHugh M. Experience with atypical antipsychotics in an acute inpatient unit: focus on quetiapine. Int J Psychiatry Clin Pract 2006; 10: 138–41
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13(2)261–76
   PubMed Web of Science ®Google Scholar
• Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 1988; 23(1)99–110
   PubMed Web of Science ®Google Scholar
• Peralta V, Cuesta MJ, de Leon J. Positive and negative symptoms/syndromes in schizophrenia: reliability and validity of different diagnostic systems. Psychol Med 1995; 25(1)43–50
   Google Scholar
• Leucht S, Engel RR. The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in Antipsychotic Drug Trials. Neuropsychopharmacology 2006; 31: 406–12
   Google Scholar
• Barnes TRE. The Barnes Akathisia Rating Scale – Revisited. J Psychopharmacol 2003; 17(4)365–70
   PubMed Web of Science ®Google Scholar
• Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672–6
   PubMed Web of Science ®Google Scholar
• Janno S, Holi MM, Tuisku K, Wahlbeck K. Validity of Simpson–Angus Scale (SAS) in a naturalistic schizophrenia population. BMC Neurol 2005; 5: 5
   PubMed Web of Science ®Google Scholar
• Hawley CJ, Fineberg N, Roberts A, Baldwin D, Sahadevan A, Sharman V. The use of the Simpson Angus Scale for the Assessment of movement disorder: a training guide. Int J Psychiatry Clin Pract 2003; 7(4)349–2257
   PubMed Web of Science ®Google Scholar
• Tandon R. Safety and tolerability : how do newer generation ‘atypical’ antipsychotics compare?. Psychiatr Q 2002; 73: 297–311
   PubMed Web of Science ®Google Scholar
• Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 2001; 23: 1839–54
   PubMed Web of Science ®Google Scholar
• DelBello MP, Schwiers ML, Rosenberg HL, Strakowski SM. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatmetn for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002; 41: 1216–23
   PubMed Web of Science ®Google Scholar
• McConville B, Carrero L, Sweitzer D, Potter L, Chaney R, Foster K, Sorter M, Friedman L, Browne K. Long-term safety, tolerability and clinical efficacy of quetiapine in adolescents: an open-label extension trial. J Child Adolesc Psychopharmacol 2003; 13: 75–82
   PubMed Web of Science ®Google Scholar
• Pae CU, Ghaemi SN, Kim TS, Kim JJ, Lee SJ, Lee CU, Lee C, Paik IH. Rapid titration versus conventional titration of quetiapine in the treatment of bipolar mania: a preliminary trial. J Clin Psychiatry 2007; 68: 399–405
   PubMedGoogle Scholar
• Mauri MC, Volonteri LS, Fiorentini A, Pirola R, Bareggi SR. Two weeks’ quetiapine treatment for schizophrenia, drug-induced psychosis and borderline personality disorder: a naturalistic study with drug plasma levels. Expert Opin Pharmacother 2007; 8: 2207–13
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy Chr, Weiden P, Strakowski SD. Efficacy and tolerability of olanzapine, quetiapine and risperidone in the treatment of early psychosis: a randomised, double-blind 52-week comparison. Am J Psychiatry 2007;164:1050–60.
   PubMed Web of Science ®Google Scholar